VTYX Ventyx Biosciences Inc.

Biotech Analyst Ratings

Latest News

1. 12 May 2022 Ventyx Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress

   Topline Phase 1 data for our allosteric TYK2 inhibitor, VTX958, expected in early Q3 2022
   

   Topline Phase 1 data for our selective NLRP3 inhibitor, VTX2735, expected in Q2 2022

   Announced the appointment of William Sandborn, MD, as President and Chief Medical Officer, strengthening our deep expertise in immunology

   ENCINITAS, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced financial results for the first quarter ended March 31, 2022 and highlighted recent pipeline and business progress.

   "I am proud of our team's continued…

   View Full Article
2. 09 May 2022 Ventyx Biosciences Announces Appointment of William Sandborn, MD, as President and Chief Medical Officer

   ENCINITAS, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced the appointment of William Sandborn, MD, as President and Chief Medical Officer.
   

   "I am delighted to welcome Bill to the Ventyx leadership team," said Raju Mohan, CEO. "In addition to being an accomplished physician, a world-renowned immunologist and an expert in the field of inflammatory bowel disease, Bill has also played a key role in the development of a number of approved therapies in the immunology space, both small-molecules and biologics. As Chairman…

   View Full Article
3. 05 May 2022 Ventyx Biosciences to Report First Quarter 2022 Financial Results on May 12, 2022

   ENCINITAS, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the first quarter ended March 31, 2022 after market close on May 12, 2022. Company management will host a conference call and webcast beginning at 4:30 p.m. ET/ 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress.
   

   To participate in the conference call, please dial (877) 788-3665 (U.S.) or (615) 489-8863 (international) and refer to conference ID 5790909. A live…

   View Full Article
4. 23 March 2022 Ventyx Biosciences Reports Full Year 2021 Financial Results and Highlights Recent Corporate Progress

   Topline Phase 1 data for our allosteric TYK2 inhibitor, VTX958, expected in early Q3 2022
   

   Topline Phase 1 data for our oral, selective NLRP3 inhibitor, VTX2735, expected in Q2 2022

   Phase 2 trial of our S1P1R modulator, VTX002, continues to enroll in ulcerative colitis (UC)

   Strong cash position with year-end cash, cash equivalents and marketable securities of $286.7M

   ENCINITAS, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced financial results for the full year ended December 31, 2021 and highlighted recent pipeline…

   View Full Article
5. 07 March 2022 Ventyx Biosciences to Participate in the Barclays Global Healthcare Conference

   ENCINITAS, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx" or the "Company"), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, announced today that Raju Mohan, Chief Executive Officer of Ventyx, will provide a company overview at the Barclays Global Healthcare Conference being held March 15-17, 2022.
   

   • Event: Barclays Global Healthcare Conference
     Location: Miami, Florida
     Date: Wednesday, March 16, 2022
     Time: 2:35-3:00 PM ET

   Members of the Ventyx management team will also host investor meetings during the conference.

   A webcast of the presentation will be available in the Investors and News…

   View Full Article